Access to Biomarker Testing Press Releases
A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.
Massachusetts cancer survivors and caregivers urge lawmakers to support legislation that will increase access to precision medicine and patient navigation for all communities.
Expanding access to this form of precision medicine will help more people in Connecticut get the right treatment at the right time.
Leading public health group urges Senate and Gov. Lamont to follow suit in ensuring biomarker testing can benefit more Connecticut patients
Leading public health group urges Senate and Gov. Lamont to follow suit in ensuring biomarker testing can benefit more Connecticut patients
Maryland state lawmakers have released details on the agreed upon 2025-26 budget—the contents of which are a mixed bag in the fight against cancer. While the state made sound investments in cancer research and protected Medicaid recipients’ ability to access biomarker testing, it missed an opportunity to save the lives and lungs of Maryland’s youth by cutting funding for the state’s tobacco prevention and cessation programs.
North Carolina lawmakers have taken a critical step in efforts to reduce the cancer burden by introducing House Bill 567.
Yesterday, both chambers in the New Jersey State Legislature passed legislation (Assembly Bill 4163 / Senate Bill 3098) to increase access to biomarker testing, which can help determine the best treatment plan for each patient. The bill will now go to Governor Murphy’s desk, providing him the opportunity to ensure coverage of this essential testing for more New Jerseyans. The American Cancer Society Cancer Action Network (ACS CAN) is leading the efforts on this significant policy change to ensure more patients can get the testing needed to access precision medicine.
Insurance coverage of biomarker testing will reduce health disparities for cancer patients & improve outcomes across broad spectrum of serious disease
